Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Singulair by Quarter
Singulair (montelukast, legacy pre-Organon spin-off) — U.S. reported growth YoY (%) (%)
Merck Singulair: -8.0% in Q1 2021, up 3.0 pts from a year earlier. No newer figure appears in the documents we track.
Latest, Q1 2021
-8.0%
Period ended Mar 31, 2021
Change on a year earlier
+3.0 pts
-11.0% in Q1 2020
History
12 quarters
Since Q4 2017
Sources
12
Documents cited below
Where the Q1 2021 figure comes from
“|| Singulair | 107 | 155 | -31 | 4 | 5 | -8 | 102 | 151 | -32”
Source: Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Reported in Form 8-K Table 3a / 3b Product Sales.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Merck Singulair (%), quarterly Q4 2017–Q1 2021 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-singulair-us-nom-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.